Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2013
Sep. 30, 2012
Sep. 30, 2011
Cash flows from operating activities        
Net (loss) income $ 949 $ (12,634) $ 3,804 $ (5,012)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:        
Undistributed loss from equity method investment in affiliate 448    1,284 5,047
Provision for credit losses   11,000    
Unrealized gain on derivative instrument (23) (15) (73) (35)
Depreciation and amortization of intangibles 105 340 440 431
Equity-based compensation 2 7,079 15 14
Amortization of deferred financing fees   760    
Noncash gain on securitizations and payment in kind income (136) (390) (53) (1,426)
Amortization of servicing assets 70 312 352 589
Change in securitization residual assets 87 6 128 1,145
Changes in other assets and liabilities:        
Financing receivables held-for-sale   (16,444)    
Accounts payable and accrued expenses (2,638) 498 4,097 860
Other (311) (1,264) (259) (81)
Net cash (used in) provided by operating activities (1,447) (10,752) 9,735 1,532
Cash flows from investing activities        
Purchases of financing receivables (2,102) (155,992) (103,284) (7,168)
Principal collections from financing receivables 6,285 68,537 51,478 22,602
Purchases of investments   (92,522) (254) (1,011)
Principal collections from investments   558 760 1,009
Purchase of property and equipment   (65) (217) (52)
Investment in equity method affiliate (584)   (3,337) (5,120)
Distribution received from equity method affiliate 443   14,294  
Proceeds from (Advances to) affiliates 8   65 (8)
Change in restricted cash 1,980 (49,810) 265 (2,051)
Net cash used in investing activities 6,030 (229,294) (40,230) 8,201
Cash flows from financing activities        
Proceeds from nonrecourse debt 2,181 29,122 104,224 7,399
Principal payments on nonrecourse debt (6,511) (65,231) (52,118) (23,111)
Proceeds from credit facility   131,000   4,000
Principal payments on credit facility (430) (57,974) (2,296) (1,441)
Proceeds from asset-backed nonrecourse notes   100,000    
Payments on deferred funding obligations   (16,874)    
Payment of deferred financing costs   (8,712)    
Net proceeds from issuance of equity   160,031    
Repurchase of common stock   (366)    
Payment of dividends   (6,934)    
Distributions on Series A Participating Preferred Units (2,346)     (227)
Return of capital on Series A Participating Preferred Units (10,401)      
Distributions to non-controlling interest holders   (194)    
Net cash provided by (used in) financing activities (17,507) 263,868 49,810 (13,380)
Increase (decrease) in cash and cash equivalents (12,924) 23,822 19,315 (3,647)
Cash and cash equivalents at beginning of period 20,948 8,024 1,633 5,280
Cash and cash equivalents at end of period 8,024 31,846 20,948 1,633
Interest paid $ 2,051 $ 8,864 $ 9,201 $ 9,737